Novo Nordisk ® ordisk and partner competencies failure and Parkinson’s disease TRANSCEND 1 and 2 trials to evaluate stem cells impact on quality of life for people with moderate Parkinson’s disease Screening Japan 8 participants USA, Sweden, UK 40 participants Open-label transplant surgery or standard of care Double-blinded transplant surgery or sham surgery, or open-label standard of care 2 year primary endpoint 5 year follow-up TRANSCEND 1: observational study of patients with moderate PD aiming at identifying potential candidates to the interventional TRANSCEND 2 trial TRANSCEND 2: in combination with Lund University trial, a phase 1/2 trial investigating the treatment of Parkinson’s disease Primary endpoint: Number of treatment-emergent adverse events 2 years after dosing
Share
Download PDF file
